Ambrx Biopharma Inc ADR


Prices are adjusted according to historical splits.

Ambrx Biopharma Inc ADR Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$358.38 million
Book Value:
Revenue TTM:
$5.24 million
Operating Margin TTM:
Gross Profit TTM:
$7.46 million
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Ambrx Biopharma Inc ADR had its IPO on 2021-06-18 under the ticker symbol AMAM.

The company operates in the Healthcare sector and Biotechnology industry. Ambrx Biopharma Inc ADR has a staff strength of 81 employees.

Stock update

Shares of Ambrx Biopharma Inc ADR opened at $9.01 at the start of the last trading session i.e. 2023-03-31.

The stocks traded within a range of $8.76 - $9.18, and closed at $8.92.

This is a -0.45% slip from the previous day's closing price.

A total volume of 280,315 shares were traded at the close of the day’s session.

In the last one week, shares of Ambrx Biopharma Inc ADR have increased by +2.88%.

Ambrx Biopharma Inc ADR's Key Ratios

Ambrx Biopharma Inc ADR has a market cap of $358.38 million, indicating a price to book ratio of 0.1116 and a price to sales ratio of 16.5982.

In the last 12-months Ambrx Biopharma Inc ADR’s revenue was $5.24 million with a gross profit of $7.46 million and an EBITDA of $-75638000. The EBITDA ratio measures Ambrx Biopharma Inc ADR's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Ambrx Biopharma Inc ADR’s operating margin was -1487.22% while its return on assets stood at -24.66% with a return of equity of -54.12%.

In Q2, Ambrx Biopharma Inc ADR’s quarterly earnings growth was a positive 0% while revenue growth was a negative 43.3%.

Ambrx Biopharma Inc ADR’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $6.72 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ambrx Biopharma Inc ADR’s profitability.

Ambrx Biopharma Inc ADR stock is trading at a EV to sales ratio of 0.223 and a EV to EBITDA ratio of 1.0092. Its price to sales ratio in the trailing 12-months stood at 16.5982.

Ambrx Biopharma Inc ADR stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$180.87 million
Total Liabilities
$25.74 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Ambrx Biopharma Inc ADR ended 2023 with $180.87 million in total assets and $0 in total liabilities. Its intangible assets were valued at $180.87 million while shareholder equity stood at $141.89 million.

Ambrx Biopharma Inc ADR ended 2023 with $0 in deferred long-term liabilities, $25.74 million in other current liabilities, 27000.00 in common stock, $-265121000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $65.64 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.

Ambrx Biopharma Inc ADR’s total current assets stands at $121.01 million while long-term investments were $18.83 million and short-term investments were $45.25 million. Its net receivables were $2.24 million compared to accounts payable of $5.70 million and inventory worth $0.

In 2023, Ambrx Biopharma Inc ADR's operating cash flow was $-32102000.00 while its capital expenditure stood at $451500.

Comparatively, Ambrx Biopharma Inc ADR paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Ambrx Biopharma Inc ADR stock is currently trading at $8.92 per share. It touched a 52-week high of $13.07 and a 52-week low of $13.07. Analysts tracking the stock have a 12-month average target price of $5.

Its 50-day moving average was $5.72 and 200-day moving average was $2.74 The short ratio stood at 0.65 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 5946.6% are held by institutions.

Frequently Asked Questions About Ambrx Biopharma Inc ADR

The stock symbol (also called stock or share ticker) of Ambrx Biopharma Inc ADR is AMAM

The IPO of Ambrx Biopharma Inc ADR took place on 2021-06-18

Similar Industry Stocks (Biotechnology)

Last Price

Most Active

Last Price
Tesla Inc (TSLA)

Top Gainers

Last Price
Helbiz Inc (HLBZ)

Top Losers

Last Price
Imara Inc (IMRA)


Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient’s own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.


10975 North Torrey Pines Road, La Jolla, CA, United States, 92037